Orexigen Therapeutics, Inc. (NASDAQ:OREX)’s Long-Awaited Obesity Pill Contrave Received FDA Nod

Boston, MA 09/12/2014 (wallstreetpr) – The U.S. Food and Drug Administration gave a green signal to Orexigen Therapeutics, Inc. (NASDAQ:OREX) diet pill called Contrave for sale in the country. The reason why this approval holds prominence is because it is the only third kind of obesity treatment/pill in over 10 years, which has received FDA’s […]

Orexigen Therapeutics, Inc. (NASDAQ:OREX) Stock Plummets As FDA Delays Decision on Diet Drug

Boston, MA 06/12/2014 (wallstreetpr) – A bio-pharmaceutical company with a clear focus on obesity drug, Orexigen Therapeutics, Inc. (NASDAQ:OREX) announced that the drug regulator has extended time by three months for the review of the resubmitted NDA or New Drug Application for its drug Contrave. It has been directly reflected in the stock market where […]

Orexigen Therapeutics, Inc. (NASDAQ:OREX)’s Obesity Drug Approval Postponed; Shares Fell 12%

Boston, MA 06/11/2014 (wallstreetpr) – Orexigen Therapeutics, Inc. (NASDAQ:OREX) shares declined 12% as review of its experimental obesity treating drug was extended three months. Steepest Fall The U.S. Food and Drug Administration delayed its decision on Orexigen’s weight loss drug, NB32, also called Contrave, by three more months. The agency is to announce its decision […]

Why Orexigen Therapeutics, Inc. (NASDAQ:OREX) May Ride Smooth In Tricky Weight-Drug Market

Boston, MA 06/11/2014 (wallstreetpr) – Orexigen Therapeutics, Inc. (NASDAQ:OREX) intends to bring its obesity drug called Contrave to the market after the U.S. Food and Drug Administration issues its verdict today. The approval of the drug will be a milestone for the company given its many past challenges to bring the drug to the market. […]

Orexigen Therapeutics, Inc. (NASDAQ:OREX) Expecting Green Signal From FDA For NB32 New Drug Application

Boston, MA 06/05/2014 (wallstreetpr) – Orexigen Therapeutics, Inc. (NASDAQ:OREX) announced that the United States Food and Drug Administration (FDA) planned to change the action date for the NB32 New Drug Application. The company announced that the USFDA informed it that the body would reassign the Prescription Drug User Fee Act (PDUFA) action date to June […]